Deborah Keefe

5.9k total citations
130 papers, 4.3k citations indexed

About

Deborah Keefe is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Deborah Keefe has authored 130 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Cardiology and Cardiovascular Medicine, 32 papers in Endocrinology, Diabetes and Metabolism and 15 papers in Surgery. Recurrent topics in Deborah Keefe's work include Cardiac electrophysiology and arrhythmias (35 papers), Blood Pressure and Hypertension Studies (28 papers) and Hormonal Regulation and Hypertension (27 papers). Deborah Keefe is often cited by papers focused on Cardiac electrophysiology and arrhythmias (35 papers), Blood Pressure and Hypertension Studies (28 papers) and Hormonal Regulation and Hypertension (27 papers). Deborah Keefe collaborates with scholars based in United States, Switzerland and Germany. Deborah Keefe's co-authors include Steven M. Pincus, Robert E. Kates, Donald C. Harrison, Janice B. Schwartz, Md Mahmudul Hasan Khan, John C. Somberg, Dennis S. Miura, Christopher Bush, Jessica Ford and Byung‐Hee Oh and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Deborah Keefe

128 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Keefe United States	36	2.9k	1.2k	589	493	349	130	4.3k
James M. Ritter United Kingdom	43	3.3k 1.1×	816 0.7×	1.1k 1.8×	250 0.5×	1.0k 2.9×	121	6.5k
F Alhenc‐Gelas France	16	3.1k 1.1×	1.9k 1.6×	1.2k 2.0×	268 0.5×	343 1.0×	25	4.9k
Yan Gong United States	39	1.8k 0.6×	1.4k 1.2×	1.3k 2.2×	593 1.2×	695 2.0×	200	4.9k
Karl F. Hilgers Germany	41	2.5k 0.9×	1.4k 1.2×	1.3k 2.2×	197 0.4×	597 1.7×	165	5.6k
Branko Braam Canada	43	2.2k 0.7×	895 0.7×	1.7k 2.9×	379 0.8×	646 1.9×	158	5.8k
Mark T. Kearney United Kingdom	44	2.9k 1.0×	1.2k 1.0×	1.4k 2.3×	169 0.3×	733 2.1×	188	6.1k
Toshihiko Ishimitsu Japan	31	1.9k 0.6×	810 0.7×	1.3k 2.3×	193 0.4×	747 2.1×	173	4.6k
Nobuyuki Ura Japan	27	1.3k 0.4×	754 0.6×	551 0.9×	144 0.3×	329 0.9×	98	3.2k
Seiji Ueda Japan	39	1.3k 0.4×	1.1k 0.9×	949 1.6×	165 0.3×	561 1.6×	93	4.9k
Carmine Savoia Italy	33	1.6k 0.6×	862 0.7×	874 1.5×	165 0.3×	386 1.1×	79	3.5k

Countries citing papers authored by Deborah Keefe

Since Specialization

Citations

This map shows the geographic impact of Deborah Keefe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Keefe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Keefe more than expected).

Fields of papers citing papers by Deborah Keefe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Keefe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Keefe. The network helps show where Deborah Keefe may publish in the future.

Co-authorship network of co-authors of Deborah Keefe

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Keefe. A scholar is included among the top collaborators of Deborah Keefe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Keefe. Deborah Keefe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Campbell, Andrew, Ana Cristina Silva‐Pinto, Obiageli Nnodu, et al.. (2025). A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study. Blood. 146(Supplement 1). 1198–1198.

Weinmann‐Menke, Julia, Anuja Java, Deborah Keefe, et al.. (2025). #376 Evaluation of C3 deposition in patients with C3G: insights from the APPEAR-C3G Phase 3 study in patients treated with iptacopan. Nephrology Dialysis Transplantation. 40(Supplement_3). 1 indexed citations

Kimball, Alexa B., Afsáneh Alavi, Gregor B. E. Jemec, et al.. (2023). Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 7(2). s129–s129. 5 indexed citations

Alavi, Afsáneh, Gregor B. E. Jemec, Alice B. Gottlieb, et al.. (2022). Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials. 40–43. 2 indexed citations

Gottlieb, Alice B., Atul Deodhar, Iain B. McInnes, et al.. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato Venereologica. 102. adv00698–adv00698. 57 indexed citations

Sigurgeirsson, Bárður, Knut Schäkel, Chih-ho Hong, et al.. (2021). Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of Dermatological Treatment. 33(3). 1718–1726. 13 indexed citations

Boer, Rudolf A. de, et al.. (2020). Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. British Journal of Clinical Pharmacology. 86(7). 1346–1356. 35 indexed citations

Bays, Harold, Plamen Kozlovski, Qing Shao, Pieter Proot, & Deborah Keefe. (2020). Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity. 28(5). 870–881. 32 indexed citations

Shah, Amil M., Sung‐Hee Shin, Madoka Takeuchi, et al.. (2011). Left Ventricular Systolic and Diastolic Function, Remodelling, and Clinical Outcomes Among Patients with Diabetes Following Myocardial Infarction and the Influence of Direct Renin Inhibition with Aliskiren. European Journal of Heart Failure. 14(2). 185–192. 38 indexed citations

10.

Sica, Domenic, Alan H. Gradman, Ole Lederballe, et al.. (2011). Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension. Clinical Drug Investigation. 31(12). 825–837. 5 indexed citations

11.

Puig, Juan, et al.. (2009). Evaluation of the dose—response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics. 31(12). 2839–2850. 10 indexed citations

12.

McMurray, John J.V., Bertram Pitt, Roberto Latini, et al.. (2008). Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation Heart Failure. 1(1). 17–24. 276 indexed citations

13.

Jordan, Jens, et al.. (2007). Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension. Hypertension. 49(5). 1047–1055. 124 indexed citations

14.

Keefe, Deborah. (2001). Anthracycline-induced cardiomyopathy. Seminars in Oncology. 28(4J). 2–7. 113 indexed citations

15.

Alexander, H. Richard, et al.. (1991). Upper abdominal cancer surgery in the very elderly. Journal of Surgical Oncology. 47(2). 82–86. 20 indexed citations

16.

Keefe, Deborah & John C. Somberg. (1986). Esmolol: A Novel Ultra‐short‐Acting Beta‐Blocking Agent. The Journal of Clinical Pharmacology. 26(S1). A1–A2. 2 indexed citations

17.

Keren, Gad, et al.. (1986). Atrial contraction is an important determinant of pulmonary venous flow. Journal of the American College of Cardiology. 7(3). 693–695. 98 indexed citations

18.

Somberg, John C., Deborah Keefe, & Barrie Levitt. (1985). Digitalis: Its Place in Therapy. The Journal of Clinical Pharmacology. 25(7). 555–559. 2 indexed citations

19.

Levitt, Barrie & Deborah Keefe. (1985). Clinical Use of Digitalis Materials. The Journal of Clinical Pharmacology. 25(7). 507–513. 3 indexed citations

20.

Keefe, Deborah, Flora Peters, & Roger A. Winkle. (1982). Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias. American Heart Journal. 103(4). 511–518. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact